Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
A holder of PCVX common stock, James Wassil, has filed to sell 2,250 shares through UBS Financial Services on the NASDAQ on August 3, 2026, following an exercise of stock options for cash. The filing also lists prior sales over the past three months: 2,250 shares of common stock on June 1, 2026 for $111,416.62, and 2,250 shares on July 1, 2026 for $126,735.98, with the planned sale valued at $121,477.50 based on the stated aggregate market value.
Vaxcyte, Inc. chief executive Grant Pickering exercised stock options for 16,198 shares of common stock at an exercise price of $2.03 per share on July 27, 2026. He then sold 18,198 common shares in market transactions at prices between $54.77 and $56.18 per share under a Rule 10b5-1 trading plan, including sales by trusts for his children. After the derivative transaction, 137,000 option shares remain exercisable.
Grant Pickering plans to sell up to 18,198 shares of common stock of PCVX through UBS Financial Services on or about 07/27/2026, with an aggregate market value of $996,704.46. The planned sale includes 16,198 shares from an exercise of stock options and 2,000 founder shares. Recent sales over the prior three months are also listed for Pickering and two 2020 Delaware trusts associated with Claire and Benjamin Pickering, showing multiple transactions in June 2026 with specified share counts and total sale prices.
Vaxcyte, Inc. director John Markels reported a compensatory grant of 23,029 stock options, each exercisable for one share of common stock at an exercise price of $56.04 per share. The options expire on July 16, 2036 and vest over 36 months: one-third vests on July 16, 2027, and the remaining portion vests in equal monthly installments thereafter, subject to his continuous service. Following this award, he holds 23,029 derivative securities directly.
Vaxcyte, Inc. director Markels John filed an initial Form 3 reporting his beneficial ownership. The report states that he owns no Vaxcyte securities, with total direct holdings of 0 shares following the reported position. No purchases, sales, or derivative or option positions are disclosed.
Vaxcyte, Inc. announced that director Heath Lukatch will retire from its Board of Directors effective July 16, 2026, after more than eight years of service. His retirement is stated to not result from any disagreement or dispute with the company.
On the same date, the Board appointed John Markels as a Class II director, with a term expiring at the 2028 annual meeting of stockholders, and named him to the Audit Committee and Compensation Committee. The Board determined he qualifies as an independent director under Nasdaq Rule 5605(a)(2). He will be compensated under the company’s non-employee director compensation program, under which the equivalent value of the annual equity grant for all directors is currently $430,000, and has entered into the company’s standard indemnification agreement.
Vaxcyte, Inc. President and CFO Andrew Guggenhime reported an option exercise and related share sales. He exercised stock options to acquire 10,000 shares of Common Stock at $5.35 per share, then sold 10,000 shares in two open-market transactions.
The sales covered 2,087 shares at a weighted-average price of about $57.76 and 7,913 shares at a weighted-average price of about $57.16, with actual prices ranging from $56.595 to $58.32, pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026. Following these transactions, he holds 104,395 shares directly and 61,850 shares indirectly through ALG 2025 GRAT Holdings LLC.
Vaxcyte, Inc. chief operating officer Jim Wassil reported a set of transactions in the company’s common stock. He sold a total of 2,250 shares in open-market trades at weighted-average prices around the mid‑$50s per share under a Rule 10b5-1 trading plan adopted on December 9, 2025. On the same date, he exercised a stock option to acquire 516 shares at an exercise price of $5.35 per share, reducing his remaining option position. After these trades, he continues to hold a substantial stake of more than 150,000 shares of common stock, along with tens of thousands of remaining stock options.
PCVX affiliate filed a Form 144 reporting a proposed sale of 10,000 common shares. The filing lists the sale method as an Exercise of Stock Options with cash consideration on 07/06/2026. The filing also records a prior sale of 10,000 common shares on 06/18/2026 for $530,000.
PCVX reported proposed affiliate sales and recent dispositions by James Wassil.
The filing lists three prior open-market dispositions by James Wassil of 2,250 shares each on 04/01/2026, 05/01/2026, and 06/01/2026 with proceeds of $131,475.60, $127,870.65, and $111,416.62, respectively. The form also lists securities to be sold or issued to the issuer: 724 RSUs vesting 09/02/2025, 1,010 RSUs vesting 09/07/2025, and 516 shares from an exercise of stock options on 07/01/2026 (cash exercise).